December 04, 2013 | By Márcio Barra
The European medicines Agency (EMA) announced yesterday that, starting January 2014, there will be greater fee-reduction rates for orphan medicines in 2014 for big companies, something that was previously only in place for micro, small or medium-sized enterprises (SMEs).